Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Phase 2 Completed
30 enrolled
ISAKIDS
Phase 2 Terminated
67 enrolled 25 charts
Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
Phase 2 Completed
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
Phase 2 Completed
80 enrolled 13 charts
Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma
Phase 2 Completed
49 enrolled 21 charts
Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma
Phase 2 Completed
51 enrolled 5 charts
Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL)
Phase 2 Completed
16 enrolled
Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma
Phase 2 Terminated
14 enrolled 10 charts
Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma
Phase 2 Unknown
20 enrolled
Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma
Phase 2 Completed
50 enrolled
Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults
Phase 2 Terminated
2 enrolled 11 charts
FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years
Phase 2 Completed
30 enrolled 10 charts
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
Phase 2 Terminated
3 enrolled 6 charts
LAL0904
Phase 2 Completed
470 enrolled 10 charts
R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial
Phase 2 Completed
61 enrolled 8 charts
Bendamustine and Mitoxantrone in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Phase 2 Completed
60 enrolled
Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia
Phase 2 Completed
17 enrolled
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies
Phase 2 Terminated
12 enrolled 10 charts
Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma
Phase 2 Completed
213 enrolled
Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
Phase 2 Withdrawn
Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase 2 Completed
47 enrolled 10 charts
A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ≥ 60 Years
Phase 2 Completed
175 enrolled
A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma.
Phase 2 Terminated
8 enrolled 9 charts
FLE09
Phase 2 Completed
76 enrolled
ALL
Phase 2 Completed
51 enrolled
Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma
Phase 2 Terminated
30 enrolled
Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma
Phase 2 Terminated
14 enrolled 9 charts
Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma
Phase 2 Completed
30 enrolled
Use of Topotecan in Patients With Refractory Acute Leukemia
Phase 2 Completed
10 enrolled
Combination Chemotherapy in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma
Phase 2 Unknown
20 enrolled
Combination Chemotherapy With or Without Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia
Phase 2 Completed
56 enrolled
Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas
Phase 2 Completed
50 enrolled
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
Phase 2 Completed
3 enrolled
Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab
Phase 2 Terminated
15 enrolled 5 charts
Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia
Phase 2 Unknown
50 enrolled
Combination Chemotherapy Followed By Filgrastim or Sargramostim in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Phase 2 Completed
DLBCL
Phase 2 Completed
94 enrolled
Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas
Phase 2 Completed